Avidity Partners Management’s BridgeBio Pharma BBIO Stock Holding History

Avidity Partners Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$711K	Buy	+10,000	New	+$725K	0.08%	48
2025 Q3	–	Sell	-140,000	Closed	-$6.05M	–	47
2025 Q2	$6.05M	Buy	140,000 +65,000	+87%	+$2.36M	1.2%	30
2025 Q1	$2.59M	Buy	+75,000	New	+$2.53M	0.49%	50
2023 Q2	–	Sell	-1,000,000	Closed	-$16.6M	–	97
2023 Q1	$16.6M	Buy	+1,000,000	New	+$11.7M	0.55%	57
2021 Q3	–	Sell	-673,400	Closed	-$41M	–	107
2021 Q2	$41M	Sell	673,400 -141,700	-17%	-$8.09M	1.11%	33
2021 Q1	$50.2M	Buy	+815,100	New	+$53.3M	1.39%	27

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avidity Partners Management's BBIO Position: Q1 2026 in Review

Avidity Partners Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 10,000 shares worth $711K. The stake represents 0.08% of the portfolio and ranks #48 among its holdings. This is a return to the name: Avidity Partners Management previously reported a position in BBIO as recently as Q2 2025.

Avidity Partners Management first reported a position in BBIO in Q1 2021 and has held it in 6 quarters since. The position peaked at $50.2M in Q1 2021. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Avidity Partners Management held 10,000 shares of BridgeBio Pharma worth $711K as of Q1 2026.
BridgeBio Pharma was a new Avidity Partners Management position in Q1 2026.
BridgeBio Pharma made up 0.08% of Avidity Partners Management's portfolio in Q1 2026, its #48 holding.
Avidity Partners Management first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 6 quarters since.
Avidity Partners Management's BridgeBio Pharma position peaked at $50.2M in Q1 2021.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.